Keynote: How does serialization / Track & Trace play into our Pharma 4.0 and digitalization strategy?

Session

How does serialization / Track & Trace play into our Pharma 4.0 and digitalization strategy?

Keynote

Tuesday, September 24

08:45 AM - 09:15 AM

Live in Berlin

Less Details

Serialization and Track & Trace play a crucial role in our Pharma 4.0 and digitalization strategy by enhancing transparency, traceability, and compliance in the pharmaceutical supply chain. Through serialization, each individual product is assigned a unique identifier, allowing for precise tracking throughout its entire lifecycle. This not only helps in combating counterfeit drugs but also enables efficient inventory management, reduces the risk of product diversion, and ensures patient safety. By integrating serialization and Track & Trace technologies into our digitalization strategy, we can streamline operations, improve data accuracy, and meet regulatory requirements seamlessly. Ultimately, serialization and Track & Trace are key components in driving innovation and efficiency in the pharmaceutical industry as we embrace the era of Pharma 4.0. In this session you will learn:

How top provide end-to-end visibility in the pharmaceutical supply chain, enhancing transparency and traceability of products?
How to assign each product a unique identifier, enabling precise tracking from manufacturing to distribution, ensuring authenticity and reducing the risk of counterfeit drugs?
How to integrate serialization and Track & Trace systems into the Pharma 4.0 strategy for improving inventory management, streamlining operations, and enhancing overall supply chain efficiency?
How to comply with regulatory requirements by capturing and storing data related to each product’s journey, facilitating audits and ensuring adherence to quality standards?
How to enhance patient safety by enabling quick identification of products in case of recalls or quality issues, to ultimately enhance trust in pharmaceutical products?

Digitalization

Presentation

Speaker

Jyrki Syväri

Corporate Director Supply Chain Integrity, Boehringer Ingelheim International GmbH

Jyrki Syväri, Pharmacist and Chemist, made his PhD Theses in Pharmaceutical Chemistry and his Diploma in Chemistry in Analytical Chemistry. He joined Boehringer Ingelheim to become a Project Manager in Operations. He was responsible for the world-wide launches of new products, such as Metalyse and Spiriva. Thereafter he was heading a group called “Launch and Special Supplies”. In this function he was responsible for setting up supply chains for Boehringer Ingelheim’s new products. New Supply Chain paradigms and concepts fell also under his responsibility. In this context he became the world-wide program leader for BI’s Product Safety & Security project that centres around serialisation. Additionally, Jyrki is leading the global initiative Supply Chain Integrity which takes a broader view on supply chain security, transparency and Risk Management.

Join Jyrki Syväri
Book Now!

Company

Boehringer Ingelheim International GmbH

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key assets of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA.

Get Agenda

BOOK NOW